

Jean-Christophe Pignon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7002158/publications.pdf>

Version: 2024-02-01

22
papers

1,607
citations

759233

12
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

3264
citing authors

#	ARTICLE	IF	CITATIONS
1	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	30.7	488
2	Landscape of tumor-infiltrating T cell repertoire of human cancers. <i>Nature Genetics</i> , 2016, 48, 725-732.	21.4	288
3	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	7.0	193
4	p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8105-8110.	7.1	185
5	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.	7.0	154
6	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	7.0	80
7	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. <i>Cancer Immunology Research</i> , 2021, 9, 156-169.	3.4	56
8	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	7.0	49
9	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. <i>Oncotarget</i> , 2017, 8, 103428-103436.	1.8	19
10	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. <i>PLoS Genetics</i> , 2018, 14, e1007679.	3.5	14
11	p63+ ureteric bud tip cells are progenitors of intercalated cells. <i>JCI Insight</i> , 2017, 2, .	5.0	14
12	Î ¹²⁵ I-Np63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. <i>Human Pathology</i> , 2015, 46, 384-389.	2.0	13
13	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.	7.0	12
14	Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor <scp>STAT3</scp>. <i>Cancer Cytopathology</i> , 2015, 123, 696-706.	2.4	11
15	Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8⁺ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 477-477.	1.6	9
16	Cell Kinetic Studies Fail to Identify Sequentially Proliferating Progenitors as the Major Source of Epithelial Renewal in the Adult Murine Prostate. <i>PLoS ONE</i> , 2015, 10, e0128489.	2.5	7
17	Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5023-5023.	1.6	6
18	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4568-4568.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. Journal of Clinical Oncology, 2018, 36, 619-619.	1.6	2
20	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. Journal of Clinical Oncology, 2020, 38, 5010-5010.	1.6	2
21	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. Journal of Clinical Oncology, 2017, 35, 4573-4573.	1.6	1
22	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. Journal of Clinical Oncology, 2017, 35, 4576-4576.	1.6	0